Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
0.4655
-0.0040 (-0.85%)
At close: Mar 13, 2026, 4:00 PM EDT
0.4599
-0.0056 (-1.20%)
After-hours: Mar 13, 2026, 7:58 PM EDT
Fractyl Health Revenue
Fractyl Health had revenue of $3.00K in the twelve months ending September 30, 2025, down -96.91% year-over-year. In the year 2024, Fractyl Health had annual revenue of $93.00K, down -22.50%.
Revenue (ttm)
$3.00K
Revenue Growth
-96.91%
P/S Ratio
21,264.73
Revenue / Employee
$30
Employees
101
Market Cap
63.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 93.00K | -27.00K | -22.50% |
| Dec 31, 2023 | 120.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TScan Therapeutics | 10.33M |
| Alterity Therapeutics | 4.43M |
| BeyondSpring | 1.88M |
| ImageneBio | 800.00K |
| Coeptis Therapeutics Holdings | 501.00K |
| Mereo BioPharma Group | 500.00K |
| MediciNova | 409.66K |
| InflaRx | 73.73K |
GUTS News
- 16 days ago - Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance - GlobeNewsWire
- 5 weeks ago - Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts - Seeking Alpha
- 6 weeks ago - Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS - Business Wire
- 6 weeks ago - Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product - Benzinga
- 6 weeks ago - Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript - Seeking Alpha
- 6 weeks ago - Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation - GlobeNewsWire
- 2 months ago - Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness - GlobeNewsWire
- 2 months ago - Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category - GlobeNewsWire